Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.South Korea-based biopharmaceutical firm Celltrion has received approval from the FDA to serve as a contract manufacturer to produce Orencia, developed by Bristol-Myers Squibb Company, for the treatment of rheumatoid arthritis.
Subscribe to our email newsletter
The supplemental biological license application (sBLA) was submitted by Bristol-Myers Squibb Company to meet expected long-term demand for Orencia.
Jung-Jin Seo, chairman and CEO of Celltrion, said: “We are pleased to continue our strategic business partnership with Bristol-Myers Squibb. Achieving sBLA approval from the FDA to manufacture Orencia is an important milestone that reinforces our vision to become a fully integrated global biotechnology company. Celltrion is dedicated to working with our business partners to exceed their quality requirements while providing manufacturing value. It is our commitment to quality service that will attract other global biopharmaceutical companies to our manufacturing capabilities.”